疫苗ETF（159643）涨超1.3%，创新药支持政策持续加码

Group 1 - The National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, proposing 16 comprehensive support policies [1] - The government emphasizes the importance of pharmaceutical innovation, with plans to establish a commercial health insurance directory for innovative drugs by 2025 [1] - The measures allow the use of healthcare insurance data for innovative drug research and development, promoting genuine and differentiated innovation [1] Group 2 - The time for innovative drugs to enter the healthcare insurance system has significantly decreased, now averaging around one year from approval to inclusion, with approximately 80% of innovative drugs included within two years of market launch [1] - The commercial health insurance market is rapidly growing, with projected premium income reaching 977.3 billion yuan in 2024, reflecting an 8.2% year-on-year increase [1] - The measures propose 16 initiatives across five areas, including research support, healthcare insurance access, and clinical application, to foster the high-quality development of innovative drugs [1] Group 3 - The Vaccine ETF tracks the Vaccine Biotechnology Index, which includes listed companies involved in vaccine research, production, sales, and biotechnology, covering all aspects of the vaccine industry chain [2] - The index aims to reflect the overall performance of listed companies in China's vaccine and biotechnology sector, showcasing its professionalism and growth characteristics [2]